Cardiovascular health, heart failure, atherosclerosis, and cardiac research
460 articles
A novel circulating complex of two proteins independently predicts obstructive coronary artery disease, outperforming standard lipid panels.
A large-scale digital trial tests whether LLM-generated, personalized coaching prompts can boost daily physical activity better than generic messages.
A meta-analysis of 4 RCTs finds semaglutide and tirzepatide significantly reduce worsening heart failure events in obese patients within 5–6 months.
Women who experience menopause before 40 face significantly elevated cardiovascular risk — here's what clinicians need to know.
Wrist accelerometer data from 4,814 adults reveals circadian misalignment raises cardiovascular mortality risk by 68%.
A landmark NHLBI workshop synthesizes how sleep quality, duration, and circadian alignment build — or erode — cardiovascular resilience across the lifespan.
A new prediction model combining APOB/APOA1 with age, diabetes, blood pressure, and inflammation markers achieves AUC of 0.796 for calcific aortic valve disease.
A single daily polypill improved ejection fraction and cut hospitalizations 60% vs. standard care in HFrEF patients.
Senescent macrophages and cell death pathways fuel atherosclerosis — and new drug targets may finally interrupt the cycle.
The CLEAR Harmony trial tested bempedoic acid's safety in statin-intolerant patients with uncontrolled LDL and high cardiovascular risk.
A 20-year study of 1,801 American Indians links specific plasma lipid species to diastolic heart aging and coronary heart disease risk.
A real-world study of 37,000+ matched patients finds GLP-1 receptor agonists dramatically reduce cardiovascular events in obese adults with OSA.
